Q2 FY2026 EarningsQ2 FY2026 missed revenue and operating loss consensus, as the company reported zero revenue vs. $0.13M expected and an operating loss of -$4.03M vs. -$3.48M expected. However, GAAP EPS of -$0.07 significantly beat the -$0.235 consensus due to a massive increase in weighted-average shares following a Q1 private placement. A robust cash position of $41.2M provides a runway into Q1 2028, supporting accelerated Phase 1 enrollment for APR-1051.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aprea Therapeutics(APRE) the Revenue is 0 (-100%), Miss estimate;the EBIT is -4.032 M (-19.02%), Miss estimate;the EPS is -0.07 (+86.79%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B100.00%
0.00B7.10%
-0.00B107.10%
EBITMiss expectations
-0.00B19.02%
-0.00B2.66%
-0.00B16.36%
EPSExceed expectations
-0.0786.79%
-0.23555.66%
+0.165031.13%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf